Research
Saccharomyces boulardii (S. boulardii)
87 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Efficacy and Safety of <em>Saccharomyces Boulardii</em> with Standard Quadruple Therapy for Eradication of <em>Helicobacter Pylori </em>in Adults: Meta-Analysis.
Meta-analysis of 11 RCTs involving 2,295 patients evaluating Saccharomyces boulardii as an adjunct to standard bismuth-containing quadruple therapy for Helicobacter pylori eradication. The addition of S. boulardii significantly improved eradication rates and reduced treatment-related adverse events, including diarrhea and rash.
Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication.
Meta-analysis of ten randomized controlled trials assessing the effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication. S. boulardii significantly improved eradication rates and reduced adverse effects such as diarrhea, constipation, and nausea.
Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation.
RCT evaluating the efficacy and safety of adding Saccharomyces boulardii to standard H. pylori eradication therapy. The 10-day probiotic treatment showed higher eradication rates compared to non-probiotic treatment, but not the 14-day regimen. S. boulardii reduced the frequency of adverse events, particularly diarrhea, in the 14-day regimen, though significance was lost after adjustment.
Epidemiology of Saccharomyces fungemia: A systematic review.
Systematic review of 117 cases of Saccharomyces fungemia, with 108 included in the analysis. The review highlights that Saccharomyces fungemia is commonly associated with S. boulardii probiotic use, particularly in patients with intensive care unit stays, total parenteral nutrition, gastrointestinal symptoms, and diabetes mellitus. The all-cause mortality rate was 36.1%, with no significant difference between those treated with S. boulardii probiotics and those not.
Effectiveness and Safety of Saccharomyces Boulardii for the Treatment of Acute Gastroenteritis in the Pediatric Population: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Systematic review and meta-analysis of 10 RCTs involving 1282 children with acute gastroenteritis. Saccharomyces boulardii significantly shortened diarrhea duration, reduced hospital stay, and decreased the frequency of diarrhea without adverse reactions.
Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis.
RCT comparing Saccharomyces boulardii CNCM I-745 to a 4-strain mixture of Bacillus clausii for treating pediatric acute gastroenteritis in 317 children. S boulardii CNCM I-745 significantly reduced the mean duration of diarrhea compared to B clausii and both probiotics improved secondary outcomes and were well-tolerated.
Effect and Safety of Saccharomyces boulardii for Neonatal Necrotizing Enterocolitis in Pre-term Infants: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of 10 RCTs involving 1264 pre-term infants to assess the effect and safety of Saccharomyces boulardii for neonatal necrotizing enterocolitis (NEC). Significant reductions were found in the incidence of NEC, feeding intolerance, full feeding days, and hospitalization days in the S. boulardii group compared to control. No significant differences were observed in sepsis, mortality, and time to regain birth weight.
[Systematic review: clinical evidence of probiotics in the prevention of antibiotic-associated diarrhoea].
Systematic review evaluating the effectiveness of probiotics in preventing antibiotic-associated diarrhoea (AAD). Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG show evidence-based efficacy in preventing AAD, particularly in children and outpatient adults.
Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update.
Systematic review and meta-analysis of 29 RCTs evaluating Saccharomyces boulardii for treating acute gastroenteritis in children. S. boulardii use reduced the duration of diarrhoea and hospitalisation, though evidence quality was low to very low.
Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis.
Systematic review and meta-analysis of 18 trials with 3592 patients assessing Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication. S. boulardii supplementation significantly improved eradication rates and reduced the incidence of total side effects and gastrointestinal adverse effects, such as diarrhea and constipation.
Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea.
This systematic review and meta-analysis evaluated the effectiveness of Saccharomyces boulardii in preventing antibiotic-associated diarrhoea in children and adults. The analysis included 21 randomised controlled trials with 4780 participants, showing that S. boulardii significantly reduced the risk of antibiotic-associated diarrhoea and Clostridium difficile-associated diarrhoea, particularly in children.
Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection.
Systematic review and meta-analysis of 11 RCTs with 2200 participants assessing Saccharomyces boulardii supplementation in H. pylori eradication therapy. S. boulardii increased eradication rates and reduced therapy-related side effects such as diarrhea and nausea.
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients, analyzing 31 randomized, placebo-controlled treatment arms in 27 trials. S. boulardii was significantly efficacious and safe in 84% of treatment arms, particularly for preventing antibiotic-associated diarrhea and traveler's diarrhea. It is also supported for prevention of enteral nutrition-related diarrhea and reduction of Helicobacter pylori treatment-related symptoms.
Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment.
Meta-analysis of five RCTs involving 1307 participants assessing Saccharomyces boulardii supplementation with standard triple therapy for H. pylori eradication. S. boulardii significantly increased eradication rates and reduced therapy-related adverse effects, particularly diarrhea.
Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children.
Meta-analysis of five randomized-controlled trials with 619 participants assessing Saccharomyces boulardii for treating acute infectious diarrhoea in children. S. boulardii significantly reduced the duration of diarrhoea and the risk of diarrhoea lasting more than 7 days compared to control.
Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea.
Meta-analysis of five randomized-controlled trials with 1076 participants showed that Saccharomyces boulardii is moderately effective in preventing antibiotic-associated diarrhoea in children and adults. Treatment reduced the risk of diarrhoea from 17.2% to 6.7%, with a number needed to treat of 10.
Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial.
RCT of 120 CDI patients assessing Saccharomyces boulardii as adjunct therapy with vancomycin. The combination group had a significantly higher global cure rate and lower recurrence rate compared to vancomycin alone, without affecting functional recovery or increasing adverse events.
Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergoing pelvic radiotherapy for gynecologic cancers: a randomized controlled trial.
RCT evaluating the efficacy of Saccharomyces boulardii in preventing acute radiation-induced GI toxicities in 60 patients undergoing pelvic radiotherapy for gynecologic cancers. S. boulardii reduced type 6 and 7 stool consistency at week 3 but resulted in higher diarrhea incidence at week 4. No consistent effect was observed across outcomes, and overall efficacy remains inconclusive.
A Randomized, Controlled Study Evaluating Effects of Saccharomyces boulardii in Adult Patients with Asthma.
RCT of 50 asthmatic patients evaluating the effects of Saccharomyces boulardii added to conventional treatments. Significant improvement in FEV1 was noted in the probiotic group, along with reductions in IL-5 and IgE levels, suggesting partial improvement in pulmonary function.
Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection.
RCT assessing the effectiveness and safety of combining Saccharomyces boulardii with triple therapy for eradicating H. pylori infection in 144 patients with non-ulcer dyspepsia. The combination showed notable efficacy, reduced dyspepsia symptoms, and smaller gastrointestinal side effects compared to other treatments.
Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori.
RCT comparing the effectiveness of a vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements to a bismuth-based quadruple regimen for Helicobacter pylori eradication. The VAS group showed similar eradication rates with fewer adverse events and lower cost, particularly effective for low-BSA patients or non-smokers.
Effectiveness of phototherapy with and without probiotics for the treatment of indirect hyperbilirubinaemia in preterm neonates: a randomised controlled trial.
RCT conducted on 76 preterm neonates to evaluate the effectiveness of phototherapy with and without probiotics for treating indirect hyperbilirubinaemia. Probiotics significantly reduced the duration of phototherapy and hospital stay compared to phototherapy alone.
Saccharomyces boulardii improves clinical and paraclinical indices in overweight/obese knee osteoarthritis patients: a randomized triple-blind placebo-controlled trial.
This randomized triple-blind placebo-controlled trial studied the effect of Saccharomyces boulardii in 70 patients with knee osteoarthritis. The probiotic group showed significant improvements in pain intensity, inflammatory and oxidative stress biomarkers, and some dimensions of quality of life compared to placebo.
Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study.
This randomized open label study assessed the effect of Saccharomyces boulardii CNCM I-745 in patients with bacterial overgrowth associated with diarrhea-predominant irritable bowel syndrome. The study found that S. boulardii, combined with dietary advice, reduced bacterial overgrowth, improved digestive symptoms, and restored intestinal microbiota. The treatment was associated with an increased abundance of F. prausnitzii and marked clinical improvement.
Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.
This double-blind, randomized, placebo-controlled trial investigated the effects of Saccharomyces boulardii and Lactobacillus reuteri on Helicobacter pylori eradication and treatment adverse effects. The study included 156 patients divided into three groups, with S. boulardii significantly reducing adverse effects like nausea, diarrhea, headache, abdominal pain, and anxiety compared to the control group. Eradication rates were similar across groups.
Impact of Saccharomyces boulardii on jaundice in premature infants undergoing phototherapy.
RCT evaluating the effect of Saccharomyces boulardii supplementation on jaundice in 100 premature infants undergoing phototherapy. The treatment group showed reduced bilirubin levels, shorter duration of jaundice resolution and phototherapy, and improved bowel movements compared to the control group.
Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial.
The GutHeart trial was a multicentre, prospective randomized open label, blinded end-point trial involving 151 patients with heart failure and reduced ejection fraction. Patients were randomized to receive Saccharomyces boulardii, rifaximin, or standard of care. After three months, there were no significant differences in left ventricular ejection fraction, microbiota diversity, TMAO, or C-reactive protein between the treatment groups and the standard of care.
Do Probiotics During In-Hospital Antibiotic Treatment Prevent Colonization of Gut Microbiota With Multi-Drug-Resistant Bacteria? A Randomized Placebo-Controlled Trial Comparing Saccharomyces to a Mixture of Lactobacillus, Bifidobacterium, and Saccharomyces
RCT of 120 patients treated with amoxicillin-clavulanate antibiotics, comparing placebo, Saccharomyces boulardii, and a probiotic mixture. The probiotic mixture significantly reduced colonization with Pseudomonas and AmpC-producing enterobacteria, and no ESBL-producing bacteria infections were observed up to 2 years after the trial.
[Effectiveness of Saccharomyces boulardii combined with phototherapy in the treatment of hyperbilirubinemia in neonates: a prospective randomized controlled trial].
Prospective RCT studying the effectiveness of Saccharomyces boulardii combined with phototherapy in neonates with hyperbilirubinemia. The treatment group showed significantly lower bilirubin levels and reduced need for repeat phototherapy compared to control. Saccharomyces boulardii also positively influenced gut microbiota composition.
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea.
RCT assessing the efficacy and safety of Saccharomyces boulardii CNCM I-3799 in managing acute diarrhea in 100 infants and children. The probiotic group showed significantly shorter recovery time and improved stool consistency compared to placebo.
Clinical Efficacy Comparison of Saccharomyces Boulardii and Lactic Acid as Probiotics in Acute Pediatric Diarrhea.
RCT comparing the efficacy of Saccharomyces boulardii and lactic acid producing probiotics in treating acute diarrhea in children. Saccharomyces boulardii showed a significantly higher efficacy rate (45%) compared to lactic acid producing probiotics (26%).
Are probiotics and prebiotics effective in the prevention of travellers' diarrhea: A systematic review and meta-analysis.
Systematic review and meta-analysis of 12 RCTs on probiotics and prebiotics for preventing travellers' diarrhea. Saccharomyces boulardii CNCM I-745 significantly reduced TD incidence, while L. rhamnosus GG showed a trend and L. acidophilus showed no significant effect.
Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children.
The article provides recommendations for using probiotics, specifically Lactobacillus rhamnosus GG and Saccharomyces boulardii, to prevent antibiotic-associated diarrhea in children. Recommendations are based on a systematic review of existing systematic reviews and randomized controlled trials.
Comparison of Two Forms of Loperamide-Simeticone and a Probiotic Yeast (Saccharomyces boulardii) in the Treatment of Acute Diarrhoea in Adults: A Randomised Non-Inferiority Clinical Trial.
This randomized non-inferiority clinical trial compared the efficacy and tolerability of two loperamide-simeticone formulations and a Saccharomyces boulardii capsule in treating acute diarrhoea in adults. The loperamide-simeticone formulations were found to be superior to Saccharomyces boulardii in reducing the number of unformed stools and providing faster relief of diarrhoea and abdominal discomfort.
Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea.
Multicentre, randomised, prospective, controlled, single blind clinical trial evaluating the impact of Saccharomyces boulardii CNCM I-745 on acute watery diarrhoea in children. The probiotic significantly reduced the duration of diarrhoea, hospital stay, and emergency care unit stay compared to control, with no adverse effects noted.
Efficacy and safety of Saccharomyces boulardii for acute diarrhea.
Meta-analysis of randomized and non-randomized trials evaluating Saccharomyces boulardii for acute diarrhea in children. S. boulardii significantly reduced the duration and frequency of diarrhea, showing beneficial effects. Further studies are needed to determine optimal dosage.
Effect of Saccharomyces boulardii and Bacillus subtilis B10 on intestinal ultrastructure modulation and mucosal immunity development mechanism in broiler chickens.
RCT evaluating the effect of Saccharomyces boulardii and Bacillus subtilis B10 on intestinal ultrastructure and mucosal immunity in broiler chickens. Probiotic groups showed significant improvements in body weight, intestinal villus structure, and increased IgA-positive cells, indicating enhanced gut health and immunity.
Saccharomyces boulardii for prevention of necrotizing enterocolitis in preterm infants: a randomized, controlled study.
RCT evaluating Saccharomyces boulardii supplementation in very low-birth-weight infants for reducing necrotizing enterocolitis (NEC) and death. No significant difference in NEC or death rates, but improved feeding tolerance and reduced clinical sepsis in the probiotic group.
Efficacy of Saccharomyces boulardii on necrotizing enterocolitis or sepsis in very low birth weight infants: a randomised controlled trial.
RCT investigating the efficacy of Saccharomyces boulardii in preventing necrotizing enterocolitis (NEC) or sepsis in very low birth weight infants. The study found no significant difference in the incidence of NEC or sepsis between the S. boulardii and placebo groups.
Treatment of recurrent Clostridium difficile infection: a systematic review.
Systematic review of treatments for recurrent Clostridium difficile infection (RCDI), evaluating metronidazole, vancomycin, fidaxomicin, nitazoxanide, rifampin, immunoglobulins, probiotics, and fecal bacteriotherapy. Fecal bacteriotherapy was found to be highly efficacious. Saccharomyces boulardii may have a role as adjunctive treatment.
Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial.
A single-center, randomized, double-blind, placebo-controlled trial tested the effect of Saccharomyces boulardii on antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated diarrhea (CDAD) in hospitalized patients. The study found no significant difference in the occurrence of AAD or CDAD between the probiotic and placebo groups.
Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea.
Systematic review and meta-analysis on the use of Saccharomyces boulardii for acute infectious diarrhea. S. boulardii significantly reduced the duration of diarrhea by approximately 24 hours and hospitalization by approximately 20 hours, showing a clinically significant benefit.
Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review.
Systematic review of randomized, double-blind placebo controlled trials evaluating Saccharomyces boulardii in the prevention of Clostridium difficile infection (CDI). Some studies showed a reduction in CDI relapses, particularly in patients with recurrent CDI and concurrent high-dose vancomycin treatment. Primary prevention studies lacked statistical power. Saccharomyces boulardii was generally well tolerated, with some reports of increased thirst and constipation.
Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication.
Multicentre prospective clinical trial evaluating the efficacy and safety of Saccharomyces boulardii in preventing antibiotic-associated diarrhoea in patients undergoing H. pylori eradication. Diarrhoea rates were significantly lower in the treatment group compared to the control group, indicating S. boulardii is effective and safe for this purpose.
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial.
RCT of 269 children with otitis media and/or respiratory tract infections receiving antibiotics, comparing 250 mg of Saccharomyces boulardii to placebo. S. boulardii significantly reduced the prevalence of antibiotic-associated diarrhoea compared to placebo, with no adverse events observed.
Effects of Saccharomyces boulardii in children with acute diarrhoea.
RCT of 200 children with acute diarrhoea comparing Saccharomyces boulardii to placebo for 5 days. S. boulardii significantly reduced stool frequency, duration of diarrhoea, and hospital stay duration compared to placebo.
Invasive Saccharomyces infection: a comprehensive review.
Comprehensive review of invasive Saccharomyces infection, highlighting its association with probiotic Saccharomyces boulardii. Analyzed 92 cases, with S. boulardii accounting for 51.3% of fungemias. Infections were similar to invasive candidiasis, with favorable outcomes in 62% of cases. Caution advised for S. boulardii use.
The probiotic effect of Saccharomyces boulardii in a pediatric age group.
RCT investigating the efficacy of Saccharomyces boulardii in reducing antibiotic-associated diarrhea in pediatric patients. The study found that S. boulardii significantly decreased diarrhea rates in patients receiving antibiotics, particularly in the 1-5 years age group.
Saccharomyces boulardii supplementation does not affect anaerobic power gain induced by short-term sprint interval training in physically active individuals.
RCT investigating the effect of Saccharomyces boulardii supplementation on anaerobic power gain induced by short-term sprint interval training in 15 physically active individuals. Sb supplementation did not influence changes in peak and mean power output across two weeks of training.
Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral diarrhoea in adults: results from a single-centre randomized trial.
This randomized, placebo-controlled trial evaluated the efficacy of Saccharomyces boulardii (Sb) in treating acute inflammatory viral diarrhoea in 46 patients. The study found that 70% of patients in the Sb group reported improvement by day 4, compared to 26% in the placebo group, suggesting that Sb supplementation positively impacts symptom improvement.
The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial.
RCT of 40 MS patients examining the effect of Saccharomyces boulardii supplementation for four months. The probiotic significantly decreased hs-CRP, increased serum antioxidant capacity, and improved pain, fatigue, and quality of life compared to placebo.
Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.
This randomized, open-label trial studied the effect of Saccharomyces boulardii CNCM I-745 plus sequential therapy on Helicobacter pylori eradication. The experimental group showed a higher eradication rate (86.0% vs. 74.7%) and lower incidence of adverse events compared to the control group.
Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy
RCT of 183 patients with H. pylori infection comparing standard triple therapy alone to triple therapy plus Saccharomyces boulardii probiotic or broccoli sprout extract sulforaphane. Neither supplementation increased the eradication rate nor reduced adverse events.
[Clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia].
RCT of 88 children with diarrhea secondary to Mycoplasma pneumoniae pneumonia comparing azithromycin sequential therapy with and without Saccharomyces boulardii powder. The study group showed improved clinical symptoms, shorter hospital stays, reduced defecation frequency, and lower rates of intestinal dysbacteriosis without increased adverse events.
A double-blinded randomized trial on growth and feeding tolerance with Saccharomyces boulardii CNCM I-745 in formula-fed preterm infants.
A double-blinded randomized trial with 125 formula-fed preterm infants studied the effects of Saccharomyces boulardii supplementation. The probiotic group showed significantly higher weight gain and improved feeding tolerance compared to the control group, with no adverse effects observed.
Efficacy and Safety of Saccharomyces boulardii in Acute Rotavirus Diarrhea: Double Blind Randomized Controlled Trial from a Developing Country.
Double-blind RCT of 60 children with acute rotavirus diarrhea comparing Saccharomyces boulardii (500mg/day) to control. The intervention group had a significantly shorter duration of diarrhea and hospitalization, with no adverse events reported.
Effects of Saccharomyces boulardii on neonatal hyperbilirubinemia: a randomized controlled trial.
A randomized controlled trial investigated the efficacy of Saccharomyces boulardii supplementation on neonatal hyperbilirubinemia in 119 infants. The study found no significant difference in serum bilirubin levels or duration of phototherapy between the S. boulardii and placebo groups.
Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
This randomized, double-blind, placebo-controlled trial investigated the effects of Saccharomyces boulardii on cytokine levels and clinical symptoms in patients with diarrhea-dominant irritable bowel syndrome. The S. boulardii group showed significant improvements in proinflammatory and anti-inflammatory cytokine levels, quality of life, and histological findings compared to placebo.
Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants.
RCT comparing prophylactic Saccharomyces boulardii to nystatin in very low birth weight infants for preventing fungal colonization and invasive infections. S. boulardii was as effective as nystatin in reducing fungal colonization and more effective in reducing clinical sepsis and feeding intolerance.
Saccharomyces boulardii does not prevent relapse of Crohn's disease.
RCT of 165 patients with Crohn's disease in remission, comparing Saccharomyces boulardii to placebo over 52 weeks. No significant difference in relapse rates, time to relapse, or inflammation markers between groups. Saccharomyces boulardii was safe but did not prevent relapse.
A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
RCT of 67 IBS patients comparing Saccharomyces boulardii to placebo for 4 weeks. S. boulardii improved quality of life more than placebo, but was not superior for individual IBS symptoms.
Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial.
Double-blind RCT assessing the efficacy and safety of 250 mg Saccharomyces boulardii twice daily for 5 days in children with acute diarrhea. The SB group had a significantly shorter duration of diarrhea and earlier appearance of semi-formed stool compared to placebo.
Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children.
RCT in Bolivian children under 2 years with acute rotavirus diarrhoea comparing oral rehydration therapy plus placebo, Saccharomyces boulardii, or a probiotic mix. The single species product reduced diarrhoea and fever duration significantly compared to controls, while the mixed probiotic reduced vomiting duration.
Clinical efficacy comparison of Saccharomyces boulardii and yogurt fluid in acute non-bloody diarrhea in children: a randomized, controlled, open label study.
RCT comparing the efficacy of Saccharomyces boulardii and yogurt fluid in 55 children with acute non-bloody diarrhea. S. boulardii resulted in a shorter duration of diarrhea and a higher number of patients with normal stools by day 3 compared to yogurt fluid.
Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection.
This randomized single-blinded clinical trial compared the efficacy of Saccharomyces boulardii, metronidazole, and no treatment in children with gastrointestinal symptoms and Blastocystis hominis infection. Clinical cure was observed in 77.7% of the S. boulardii group and 66.6% of the metronidazole group by day 15, with significant improvements in symptoms and parasite presence compared to the no-treatment group.
Efficacy and safety of Saccharomyces boulardii in amebiasis-associated diarrhea in children.
RCT assessing the efficacy and safety of adding Saccharomyces boulardii to antibiotic treatment for amebiasis-associated acute diarrhea in children. The study found no significant difference in the duration of diarrhea or other symptoms between the group receiving S. boulardii and the group receiving only metronidazole. S. boulardii was well tolerated with no side effects.
Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study.
Double-blind controlled study investigating the preventive effect of Saccharomyces boulardii on antibiotic-associated diarrhea in 151 hospitalized patients. The study found a significant reduction in diarrhea incidence in the S. boulardii group compared to placebo, with no serious side effects.
Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea.
RCT assessing the efficacy and safety of Saccharomyces boulardii in children with acute diarrhoea. The S. boulardii group showed a significant reduction in the frequency and duration of diarrhoea compared to the control group, with improved stool consistency and no reported side effects.
Saccharomyces boulardii and infection due to Giardia lamblia.
A double-blind, placebo-controlled study evaluated the efficacy of Saccharomyces boulardii against Giardia lamblia infections in adult patients with giardiasis. Group 1 received metronidazole and S. boulardii, while group 2 received metronidazole and placebo. At week 2, G. lamblia cysts were detected in 17.1% of group 2 and none in group 1, suggesting S. boulardii may be effective in treating giardiasis when combined with metronidazole.
Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori.
RCT evaluating the effect of Saccharomyces boulardii plus inulin (SbI) and Lactobacillus acidophilus LB (LB) on Helicobacter pylori colonization in children. Hp was eradicated in 66% of the antibiotic group, 12% of the SbI group, and 6.5% of the LB group. S. boulardii showed a moderate but significant reduction in Hp colonization.
Enteral feeding of premature infants with Saccharomyces boulardii.
RCT of 87 preterm infants receiving formula with Saccharomyces boulardii or maltodextrins for 30 days. SB was well tolerated and improved stool flora, resembling that of breastfed infants, but did not enhance D-xylose or lipid absorption.
Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis.
Double-blind RCT comparing antibiotics alone versus antibiotics with saccharomyces boulardii in 54 patients with acute amoebiasis. The addition of saccharomyces boulardii reduced the duration of diarrhea, fever, and abdominal pain, and prevented amebic cyst detection at week 4.
Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.
An open pilot clinical trial evaluated the efficacy of Saccharomyces boulardii (SB) versus metronidazole (M) versus M + SB for 2 months in reducing gastrointestinal symptoms and SIBO in systemic sclerosis patients. SIBO was eradicated in 55% of the M + SB group, 33% of SB, and 25% of M. SB and M + SB groups showed decreased diarrhea, abdominal pain, and gas/bloating/flatulence, while M remained unchanged.
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial.
A double-blind, randomised, placebo-controlled trial investigated the impact of probiotic Saccharomyces boulardii on gut microbiome composition in 44 HIV-treated patients. The study found that 12 weeks of probiotic treatment significantly reduced plasma levels of bacterial translocation and systemic inflammation compared to placebo, suggesting a beneficial modification of gut microbiome composition.
Effect of Saccharomyces boulardii and Mode of Delivery on the Early Development of the Gut Microbial Community in Preterm Infants.
RCT examining the effect of oral administration of Saccharomyces boulardii on the intestinal microbial community in preterm infants. The study found a tendency for increased bacterial diversity at 2 and 6 weeks compared to day 0, with Actinobacteria and Bacteroidetes increasing in abundance. However, the study lacked power to detect statistical differences in the probiotic's effect.
Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial.
A double-blind, randomized, placebo-controlled trial in 44 HIV-1-infected patients with virologic suppression assessed the effects of Saccharomyces boulardii on microbial translocation and inflammation. The probiotic group showed significant decreases in LBP and IL-6 levels compared to placebo, indicating reduced microbial translocation and inflammation.
Randomized Clinical Trial: Impact of Oral Administration of Saccharomyces boulardii on Gene Expression of Intestinal Cytokines in Patients Undergoing Colon Resection.
RCT of 33 patients undergoing colon resection, comparing 7-day preoperative probiotic treatment with Saccharomyces boulardii to conventional treatment. Probiotic group showed significantly lower mucosal IL-1β, IL-10, and IL-23A mRNA levels, but no significant difference in postoperative infection rates or hospital stay length.
Saccharomyces boulardii viability and efficacy in horses with antimicrobial-induced diarrhoea.
Prospective controlled study of Saccharomyces boulardii in 21 horses with antimicrobial-associated diarrhoea. S boulardii was successfully cultured in 58.3% of treatment horses on day 3, but no statistically significant differences were found in clinical outcomes compared to control.
Effect of Saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune response.
RCT evaluating the effect of Saccharomyces boulardii in children with acute gastroenteritis. Group receiving S. boulardii showed significantly reduced stool frequency and enhanced immune response, with increased serum immunoglobulin A and decreased C-reactive protein levels.
Efficacy of Saccharomyces boulardii for treatment of horses with acute enterocolitis.
Prospective study evaluating the viability and efficacy of Saccharomyces boulardii in horses. In horses with acute enterocolitis, S. boulardii administration significantly decreased the severity and duration of gastrointestinal disease compared to placebo.
A pilot trial of Saccharomyces boulardii in ulcerative colitis.
Pilot trial assessing the efficacy of Saccharomyces boulardii in 25 ulcerative colitis patients. Patients received S. boulardii alongside mesalazine for 4 weeks. Of the 24 patients who completed the study, 17 attained clinical remission confirmed endoscopically.
Saccharomyces boulardii in maintenance treatment of Crohn's disease.
RCT evaluating Saccharomyces boulardii in the maintenance treatment of Crohn's disease. Patients treated with mesalamine plus Saccharomyces boulardii had a lower relapse rate compared to those receiving mesalamine alone, suggesting potential benefits for gut health.
Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial.
A multicenter, randomized, double-blind placebo-controlled trial assessed the preventive effect of Saccharomyces boulardii on diarrhea in critically ill tube-fed patients. Treatment with S. boulardii significantly reduced the mean percentage of days with diarrhea compared to placebo, especially in patients with risk factors for diarrhea.
Heat-Killed Saccharomyces boulardii Alleviates Dextran Sulfate Sodium-Induced Ulcerative Colitis by Restoring the Intestinal Barrier, Reducing Inflammation, and Modulating the Gut Microbiota
The study compared the effects of Saccharomyces boulardii, heat-killed S. boulardii, and S. boulardii β-glucan on DSS-induced ulcerative colitis in mice. Heat-killed S. boulardii showed superior benefits in restoring intestinal barrier function, reducing inflammation, and modulating gut microbiota, suggesting its potential as a novel therapy for UC.
Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study.
A single-arm, open-label pilot study with 12 hypercholesterolemic adults examining the effect of Saccharomyces boulardii on cholesterol and lipoprotein particles. Remnant lipoprotein particles decreased by 15.5% over 8 weeks, while other measures were not significantly altered.
[Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system].
This review article summarizes experimental studies on the molecular and immunological mechanisms of Saccharomyces boulardii CNCM I-745, focusing on its effects on the gut-associated immune system. S. boulardii stimulates immunoglobulin and cytokine release, induces immune cell maturation, binds pathogenic bacteria, neutralizes toxins, and attenuates inflammatory responses, thereby protecting the intestinal epithelial layer and reducing diarrhea-induced fluid loss.
Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.
Open trial of Saccharomyces boulardii in 13 patients with recurring C. difficile-associated colitis. Patients were treated with vancomycin and a 30-day course of S. boulardii, resulting in 85% having no further recurrences.